Treatment Selection for the High-risk Patient with Stage I NSCLC
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post on X:
“A multi-disciplinary group convened by the AATS summarizes an expert panel’s considerations when recommending sub-lobar resection, SBRT, or IGTA for high-risk stage I NSCLC.
The 23 participants included specialists in thoracic surgery, radiation oncology, interventional radiology, and pulmonology.
The one vignette everyone agreed on (100%) was that patient preferences are paramount.
“Here are the results for the other vignettes, demonstrating areas of disagreement, with percentages likely reflecting unbalanced specialty representation on the panel.”
Treatment Selection for the High-risk Patient with Stage I Non-Small Cell Lung Cancer: Sublobar Resection, Stereotactic Ablative Radiotherapy or Image-guided Thermal Ablation?
Authors: Arjun Pennathur, et al.
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023